Medicines Co. (MDCO) Posts Q1 Loss of $1.03/Share

The Medicines Company Reports First-Quarter 2016 Business and Financial Results

Four potential blockbuster R&D programs advancing toward key data disclosures in 2016 The announced divestiture of non-core cardiovascular assets to Chiesi Farmaceutici S.p.A. will sharpen strategic focus and significantly strengthen financial position to drive further development of R&D programs without diluting shareholders Newly launched hospital products being introduced in multiple geographic and therapeutic markets

PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) today announced its business and financial results for the first quarter ended March 31,... More

The Medicines Company Agrees to Divest Non-Core Cardiovascular Assets to Chiesi Farmaceutici S.p.A.

Chiesi will acquire Cleviprex® (clevidipine) injectable emulsion, Kengreal® (cangrelor) and rights to Argatroban for Injection Total consideration of up to $792 million and anticipated reduction in annual SG&A and related R&D expenses of between $65 million and $80 million Transaction will sharpen strategic focus on the Companys four potential blockbuster R&D products and significantly strengthen the Companys financial position with non-dilutive capital Transaction is a major step in executing on the Companys previously-announced strategic plan... More